| Recruiting | Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disea NCT07228364 | AstraZeneca | Phase 1 |
| Recruiting | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participa NCT06902558 | AbbVie | Phase 2 |
| Recruiting | Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease NCT06435858 | Cantonal Hospital Graubuenden | Phase 2 |
| Active Not Recruiting | Role of ROS and cAMP-PKA Biomarkers in ADPKD NCT07217158 | Mayo Clinic | — |
| Enrolling By Invitation | Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease NCT05870007 | Taipei Medical University Shuang Ho Hospital | Phase 2 |
| Recruiting | Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PK NCT04939935 | The University of Queensland | Phase 3 |
| Completed | A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease NCT05521191 | Regulus Therapeutics Inc. | Phase 1 |
| Completed | Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Se NCT05190744 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Renal Denervation in ADPKD- RDN-ADPKD Study NCT05460169 | University of Erlangen-Nürnberg Medical School | N/A |
| Active Not Recruiting | Intrarenal Microvasculature in ADPKD NCT05288998 | Mayo Clinic | — |
| Active Not Recruiting | A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD NCT05193981 | Mayo Clinic | — |
| Terminated | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease NCT04578548 | Galapagos NV | Phase 2 |
| Recruiting | NOX4 and Related Biomarkers in ADPKD NCT04630613 | Mayo Clinic | — |
| Recruiting | Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT04344769 | Mayo Clinic | — |
| Completed | Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease NCT04284657 | University of Southern California | Phase 2 |
| Completed | Tolvaptan-Octreotide LAR Combination in ADPKD NCT03541447 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | ADPKD Alterations in Hepatic Transporter Function NCT03717883 | University of North Carolina, Chapel Hill | — |
| Completed | The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease NCT03487913 | Palladio Biosciences | Phase 2 |
| Enrolling By Invitation | Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository NCT03901521 | Weill Medical College of Cornell University | — |
| Completed | ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure? NCT03970018 | CHU de Reims | — |
| Completed | Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With NCT03493802 | Mayo Clinic | — |
| Withdrawn | The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Auto NCT02746419 | University of Chicago | N/A |
| Unknown | Efficacy of Tolvaptan on ADPKD Patients NCT02729662 | Kyorin University | N/A |
| Unknown | A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe NCT02848521 | Otsuka Pharmaceutical Europe Ltd | — |
| Completed | High Water Intake in Polycystic Kidney Disease NCT02933268 | Cambridge University Hospitals NHS Foundation Trust | N/A |
| Completed | Effect of the Aquaretic Tolvaptan on Nitric Oxide System NCT02527863 | Regional Hospital Holstebro | Phase 2 |
| Completed | New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease NCT02250287 | Mayo Clinic | — |
| Completed | The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Re NCT02134899 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 NCT02160145 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Clinical Implications of DNA Analysis on ADPKD NCT02322385 | Kyorin University | — |
| Withdrawn | Repository Study of Autosomal Dominant Polycystic Kidney Disease NCT01988038 | The Rogosin Institute | — |
| Unknown | Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control NCT01932450 | Mei changlin | Phase 2 |
| Unknown | The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe NCT02187432 | Andreas L. Serra | — |
| Completed | A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD) NCT01810614 | University of Kansas | N/A |
| Completed | Pasireotide LAR in Severe Polycystic Liver Disease NCT01670110 | Mayo Clinic | Phase 2 |
| Completed | 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT01451827 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Completed | Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insuff NCT01377246 | Mario Negri Institute for Pharmacological Research | Phase 3 |
| Completed | Efficacy Study of Water Drinking on PKD Progression. NCT01348035 | Kyorin University | — |
| Completed | Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD NCT01210560 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Completed | Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Diseas NCT01336972 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Unknown | Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Pat NCT02887729 | University Hospital, Brest | — |
| Recruiting | National Registry of Rare Kidney Diseases NCT06065852 | UK Kidney Association | — |
| Completed | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (A NCT01022424 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Terminated | Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Pre NCT00920309 | Yale University | Phase 2 / Phase 3 |
| Completed | Effects of Somatostatin on Liver in ADPKD NCT02119052 | Federico II University | Phase 2 / Phase 3 |
| Completed | Effects of Somatostatin on ADPKD Heart NCT02119013 | Federico II University | Phase 2 / Phase 3 |
| Completed | Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT00759369 | University of Kansas | N/A |
| Completed | Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosom NCT00414440 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease NCT00598377 | Istanbul University | N/A |
| Completed | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (A NCT00841568 | Otsuka Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease NCT01039987 | University of Pittsburgh | — |
| Completed | ADPKD Cohort Study NCT02084849 | Emory University | — |